.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AB03_Afelimomab.Afelimomab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AB03_Afelimomab.Afelimomab| name: | Afelimomab | |
| ATC code: | L04AB03 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 1 | mg |
| volume of distribution: | 0.15 | L |
| clearance: | 0.05 | L/h/kg |
| other parameters in model implementation | ||
Afelimomab is a recombinant monoclonal antibody fragment (F(ab')2) directed against tumor necrosis factor-alpha (TNF-α). It was developed for the adjunctive treatment of sepsis and septic shock by neutralizing TNF-α-mediated inflammatory responses. Afelimomab is not currently approved or in therapeutic use, as clinical development was discontinued.
Estimated pharmacokinetic parameters for adult subjects, based on typical monoclonal antibody fragment (F(ab')2) pharmaco-kinetics and publicly available summary data; no peer-reviewed publication with detailed human PK model available.